Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education

Front Page



UK Politics







Talking Point

In Depth

On Air

Low Graphics

Tuesday, November 9, 1999 Published at 00:54 GMT


Schizophrenia drug 'stimulates brain activity'

About 1% of the population has schizophrenia

The first study of how a new schizophrenia drug affects key areas of the brain could herald new treatments for the condition which affects 1% of the UK population.

Campaigners say it also adds weight to their calls for newer anti-psychotic drugs to be made more available to patients in the wake of concerns about rationing.

Mental Health
The new research suggests risperidone - one of a number of recent anti-psychotic treatments - improves activity at the front of the brain.

Scientists used brain imaging techniques to track how the drug acted on the prefrontal cortex, which is thought to control human thought processes.

Older schizophrenia drugs have been shown to control some of the thought processes associated with the condition, such as halluncinations and delusions.

But many have side effects, including a Parkinson's disease-like syndrome.

Side effects

Newer drugs like risperidone reduce apathy and social withdrawal, improve patients' ability to think clearly and rarely have severe side effects.

However, until now there have been no studies on humans of how the drugs work on the brain.

In an article in the US magazine, the Proceedings of the National Academy of Science, researchers from the University of Cambridge and the Institute of Psychiatry in London provide the first proof that substituting risperidone for the older drugs increases frontal lobe activity in schizophrenics who were asked to perform a memory-related task.

The researchers also found risperidone was slightly more effective at improving patients' health and memory.

They used functional magnetic resonance imaging, a technique for taking repeated "snapshots" of the brain over time.

These snapshots reveal changes in blood flow and oxygen levels and reflect activity in different parts of the brain.

The researchers believe their findings may open up new avenues for investigation into schizophrenia treatments and will mean doctors will be able to map how different drugs affect an individual's brain.


Cliff Prior, chief executive of the National Schizophrenia Fellowship welcomed the new research and said it boosted calls for newer schizophrenia drugs to be made more available.

The organisation has expressed concerns that the drugs are being rationed by the NHS because they tend to be more expensive than older treatments.

Mr Prior said: "It is encouraging to see research which focuses more on people's quality of life than symptom control alone. 

When NICE [the National Institue for Clinical Excellence] evaluates treatments for schizophrenia the views of the real 'experts', people prescribed anti-psychotics, must be the focal point. 

"Many people taking older drugs complain of heavy sedation.   Given the choice, treatments which cause less of this problem are very welcome." 

Advanced options | Search tips

Back to top | BBC News Home | BBC Homepage | ©

Health Contents

Background Briefings
Medical notes

Relevant Stories

14 Oct 99 | Mental health
Trust defends itself from rationing claims

20 Nov 98 | Medical notes
Schizophrenia: The facts

14 Apr 99 | Health
Mentally ill 'need more rights'

Internet Links

National Schizophrenia Fellowship

Proceedings of the National Academy of Sciences

Department of Health

The BBC is not responsible for the content of external internet sites.

In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99